Myriad says trial date not scheduled after injunctive relief denied Myriad Genetics confirmed earlier today that the U.S. District Court for the District of Utah denied its motion for preliminary injunctive relief. Myriad alleges that Ambry Genetics' testing services infringe various patent claims owned by the BRCA patent owners which relate to the BRCA1 and BRCA2 genes, and were seeking a preliminary injunction to prevent Ambry from selling the testing services. The company said, "We believe the BRCA patents at issue in this case are valid, enforceable and infringed, and are confident we will prevail based on the full evidence. A trial date has not been scheduled." Shares of Myriad are down 9%, or $3.58, to $34.17 in early trading.